Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Phoenix Children’s Researchers Identify Fibrotic Pericytes and FOXF1 as a Potential Target in Pulmonary Fibrosis
Researchers at Phoenix Children’s identified a fibrosis-associated pericyte population absent from healthy lungs and its regulator, FOXF1. Tatiana Kalin, MD, PhD, and Vlad Kalinichenko, MD, PhD, explain the preclinical findings published in Nature Communications.
To identify pericyte changes associated with pulmonary fibrosis and investigate FOXF1’s role in regulating those changes.
Approach:
Cell identification: Researchers used single-cell RNA sequencing and tissue staining to examine human lung datasets and mouse models, identifying normal Peri1 pericytes and a Peri2 population found only in fibrotic lungs.
Functional studies: They tested the effects of removing or increasing FOXF1 in pericytes in mouse fibrosis models and examined how signals from human pericytes affected fibroblasts in laboratory experiments.
Key Findings:
Peri2 cells had reduced normal pericyte markers and increased collagen and other scar-related genes; FOXF1 levels were reduced in these cells.
Removing FOXF1 from pericytes worsened fibrosis-related outcomes in mouse models.
Increasing FOXF1 in mice reduced lung collagen and scarring and improved measures including oxygen levels, including when raised after injury.
Human pericytes lacking FOXF1 released signals that increased fibroblast movement, multiplication, and scar-related gene activity.
Interpretation:
The study identifies a fibrotic pericyte population and a FOXF1-related signaling pathway as potential research targets. The cause-and-effect findings are preclinical; human data show an association between lower FOXF1 and more severe disease, not treatment benefit.
Limitations:
The FOXF1 intervention findings come from mouse models and laboratory-grown human pericytes; they do not establish that treatment would reverse pulmonary fibrosis in patients.
Further work is needed to identify drug targets, test them in additional models and patient lung tissue, develop pericyte-specific delivery, and assess safety.
Conclusion:
The authors describe FOXF1 and related pericyte signaling genes as possible targets for future investigation. Clinical trials would require additional preclinical research.